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Appropriateness of learning curve for carotid
artery stenting: An analysis of periprocedural
complications
Fabio Verzini, MD, Piergiorgio Cao, MD, FRCS, Paola De Rango, MD, Gianbattista Parlani, MD,
Agostino Maselli, MD, Lydia Romano, MD, Lucia Norgiolini, MD, and Giuseppe Giordano,
MD, Perugia, Italy
Objectives: Cerebral embolism is the first cause of neurologic complications of carotid artery stenting (CAS). A large
debate has been raised to identify the caseload necessary for an appropriate learning curve before systematic use of CAS.
This study examined (1) the timing of periprocedural complications during CAS and how these complications vary over
time to identify factors that contribute to neurologic morbidity and (2) a sufficient number of procedures for adequate
training.
Methods: During 2001 to 2006, 627 CAS procedures with cerebral protection devices (CPD) were performed in a single
vascular surgery center by a team including a vascular surgeon and an interventional radiologist. These represented 38%
of a total of 1598 carotid revascularizations performed in the same interval. CAS procedures were divided into two groups
according to time interval: the first period, 2001 to 2003, included 195 CAS procedures, and the second period, 2004 to
2006, included 432 CAS procedures. During each CAS procedure, five major steps were considered: phase 1, or the
catheterization phase, included the passage of the aortic arch, catheterization of the target vessel, and introduction of a
guiding catheter or sheath. Phase 2, or the crossing stenosis phase, included the placement of a CPD. Phase 3, or the stent
ballooning phase, included predilation (when indicated), stent implantation, postdilation, and recovery of the protection
system. Phase 4, or the early postinterventional phase, included the first 24 hours after leaving the catheterization table.
Phase 5, or the late postinterventional phase, included the interval from the first postoperative day to 30 days.
Results: At 30 days, 10 major strokes (2 of which were fatal) and 1 cardiac death occurred, for an overall major
stroke/death rate of 1.75%. Furthermore, 18 minor strokes (2.9%) were recorded. By analyzing the occurrence of major
strokes according to the three intraprocedural phases, four occurred in phase 1 and six in phase 3. All strokes but one were
ischemic; six were ipsilateral, three were contralateral, and one was posterior. Minor strokes occurred prevalently after the
procedure (11 in phase 4, 5 in phase 5, and 1 for phases 1 and 3). Comparing the first with the second interval of the study
period, the 30-day major stroke and death rate decreased from 3.1% to 0.9% (P  .047), and the 30-day any stroke and
death rate decreased from 8.2% to 2.7% (P .005). According to multivariate analysis, study interval (hazard ratio, 3.68;
95% confidence interval, 1.49-9.01; P  .005) and age (hazard ratio, 1.06; 95% confidence interval, 1.00-1.12; P  .05)
were significant predictors of stroke.
Conclusions: A large proportion of major strokes (4/10) from CAS cannot be prevented by using CPD, because these
strokes occur during catheterization (phase 1). This finding, together with the significant decrease in the overall
stroke/death rate between the first and the last interval of the study period, enhances the importance of an appropriate
learning curve that involves a caseload larger than that generally accepted for credentialing. The noticeable number of
postprocedural cerebral embolizations leading to minor strokes and occurring in the early and late postinterventional
phases (16/18) is likely due to factors less strictly related to the learning-curve effect, such as stent design and medical
therapy. Moreover, expertise in selecting material and design of the stents according to different vessel morphology, in
association with correct medical treatment, may be useful in reducing the number of minor strokes that occur in the later
postinterventional phases of CAS. (J Vasc Surg 2006;44:1205-12.)Carotid artery stenting (CAS) is becoming increasingly
common for the treatment of carotid stenosis because
accumulating (but not randomized) data suggest that CAS
has promising efficacy in preventing stroke, with an accept-
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doi:10.1016/j.jvs.2006.08.027able rate of procedure-related complications when com-
pared with carotid endarterectomy (CEA). However, CAS
procedures can carry a risk of nonnegligible complications;
the most frequently encountered are generally due to brain
embolism during catheter, wire, or sheath manipulation in
the aortic arch and through the carotid artery.1 These
strokes, occurring before or after cerebral protection device
(CPD) placement, depend on multiple factors such as
patient selection, material choices, and, ultimately, the
operator’s skills. All these data enhance the importance of
an appropriate learning curve, but there is still debate to
identify the caseload necessary before systematic use of
CAS. The aim of this study was to evaluate the extent of
experience required to ensure the safety of CAS procedures
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affecting neurologic morbidity.
SUBJECTS AND METHODS
From May 2001 to April 2006, a total of 627 CAS
procedures were performed in 570 patients (57 staged and
bilateral) in a single vascular surgery center. These repre-
sented an overall rate of 39% of 1598 carotid revasculariza-
tions performed in the same interval (Fig 1). By using the
same 2% threshold rate for major stroke achieved with
CEA,2,3 CAS procedures were divided into two groups
based on time interval. The first period, 2001 to 2003,
included 195 CAS procedures, and the second period,
2004 to 2006, included 432 CAS procedures, in which the
major stroke risk remained stable (2%). All patient data
were systematically collected in a prospective database in-
cluding preprocedural, intraprocedural, and follow-up in-
formation. The primary criterion for treatment was either
symptomatic (60%) or asymptomatic (70%) internal
carotid artery stenosis.
Preoperative evaluation. All patients underwent di-
agnostic carotid duplex ultrasonography (US) within 1
month before carotid revascularization. Duplex US scan-
ning was performed by experienced vascular surgeons,
who defined the site, degree and length of stenosis,
plaque characteristics, and vessel measurements to select
the proper size of the balloon and stent. On the basis
of duplex examination, plaques were divided into three
groups: echolucent, echogenic, and mixed (including a
similar amount of echolucency and echogenicity). Preop-
erative diagnostic digital arch aortography, cerebral com-
puted tomography (CT) scan, and supra-aortic vessel spiral
CT scan were used selectively. Patients scheduled for CAS
received full antiplatelet therapy consisting of clopidogrel
(loading dose of 300 mg within 12 hours before the
procedure and then 75 mg/d) in addition to aspirin (mean
dose of 125 mg/d).
Operative techniques. All CAS procedures were per-
formed with patients under local anesthesia in an operating
Fig 1. A total of 1598 carotid procedures: carotid artery stenting
(CAS) and carotid endarterectomy (CEA).room equipped with a digitalized portable C arm or a fixedangiographic facility (for the last 150 cases) by a team
consisting of 1 vascular surgeon and 1 interventional radi-
ologist, who had much experience in aortic arch diagnostic
and endovascular procedures before beginning to perform
carotid stenting. However, most of the procedures (76%)
were conducted by the senior vascular surgeon (P.C.).
Arterial access was transfemoral for all but nine proce-
dures, for which left brachial artery was used because of
severe obstruction in the iliac/femoral vessels. During
CAS, the patient’s neurologic status was checked continu-
ously by having the patient squeeze a toy in the appropriate
hand and by talking to the patient. Transcranial Doppler
monitoring (4040 Pyoneer Eme; Nicolet/EME, Wein-
heim, Germany) was applied when possible (330/627;
53%).
Procedures started with a diagnostic angiogram of the
aortic arch followed by selective catheterization of aortic
arch vessels in double projection. Intravenous heparin 100
U/kg was given before selective catheterization of the
common carotid artery. Intracranial images were routinely
obtained before and after the intervention to confirm pa-
tency of intracranial vessels.
CAS was performed after proper placing of CPD under
roadmap guidance. Seven different protection systems were
used: FilterWire EZ system (n  470, 75%; Boston Scien-
tific, Natick,Mass), TRAP Filter (n 30, 5.6%;Microvena,
White Bear Lake, Minn), EV3 SpideRX Filter (n 5, 0.9%;
Plymouth, Minn), Angioguard RX Filter (n 103, 17.3%;
Johnson and Johnson–Cordis, Warren, NJ), Rubicon Filter
(n  3, 0.5%; Rubicon Medical Inc, Salt Lake City, Utah),
MO.MA system (n 7, 1%; Invatec, Brescia, Italy), and Rx
Accunet Guidant Filter (n  1, 0.17%; Guidant, Santa
Clara, Calif). The stenosis was crossed with a 0.014-inch
guidewire (either a CPD distal filter guidewire or an ex-
change guidewire) over which the stent and angioplasty
balloon were advanced. Predilation (balloon dilation be-
fore delivery of the stent) was performed at the discretion of
the operator in 64 (10.2%) cases.
In all patients, self-expandable stents were used: 430
(73%) carotid Wallstents (Boston Scientific), 155 (25%)
Precise stents (Johnson and Johnson-Cordis), 3 (0.5%)
Acculink stents (Guidant), 3 (0.5%) NexStents (Boston
Scientific), 2 (0.3%) Conformexx stents (Bard,MurrayHill,
NJ), and 2 (0.3%) Exponent stents (Medtronic AVE, Santa
Rosa, Calif). The selection of the stent depended on oper-
ator preference, lesion characteristics, and commercial
availability.
Stent size conformed to the largest diameter of the
artery to be treated according to the preoperative measure-
ments of the artery by US examination. Intravenous atro-
pine (mean dose, 1 mg intravenously) was used in 444
procedures (70.8%) just before balloon inflation, at the
discretion of the anesthesiologist. After retrieval, CPDs
were visually checked for debris.
Procedural success for CASwas defined as stent deploy-
ment with resolution of stenosis or with residual stenosis
less than 30% at the completion angiogram in double
projection. Arterial access hemostasis was obtained by using
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(Abbott Laboratories, Abbott Park, Ill) and 28 Angioseal
(St Jude Medical, Inc, St Paul, Minn) devices.
Patients were evaluated at the end of the procedure,
monitored, and routinely discharged the following day,
with the exception of those with complications. Clinical
and US examinations were performed before discharge, at
1 month, and every 6 months after the procedure. In the
case of symptoms or uncertainty, all patients were examined
by a neurologist, and the necessary diagnostic imaging was
performed (CT scan or magnetic resonance imaging). The
same team of stroke neurologists evaluated patients with
clear or suspected symptoms before and after the proce-
dure. Patients continued taking aspirin and clopidogrel (75
mg/d) for 30 days after the procedure, and aspirin was
continued for life.
Definition of outcome and complications. Outcome
measures were stroke, death, cardiac events, and local com-
plications. Perioperative stroke was defined as any new
neurologic event persisting for longer than 24 hours and
occurring within 30 days from the procedure.4 Strokes
were classified as fatal, major (requiring a significant mod-
ification of lifestyle for 1 month after onset), or minor
(symptoms without significant modification of lifestyle as
evaluated by a neurologist). Transient ischemic attack (TIA)
was defined as any new retinal or hemispheric focal event
with complete recovery within 24 hours. TIAs were re-
corded but not considered as primary end points of the
study.
Myocardial infarction was diagnosed with the occur-
rence of a new Q wave in two or more leads and/or the
presence of increased enzymes (including creatine phos-
phokinases and troponins) routinely tested. To precisely
define the timing of occurrence of complications, fivemajor
steps were identified for each procedure. Phase 1, or the
catheterization phase, included the passage of the aortic
arch, catheterization of the target vessel, and introduction
of a guiding catheter or sheath. Phase 2 included crossing
the stenosis and placement of CPD. Phase 3 included
predilation (when indicated), stent implantation, postdila-
tion, and recovery of the protection system. Phase 4, or the
Table I. Risk factors in the two study periods
Variable
Overall
(n  627)
2001-200
(n  195
Mean age (y) 72.1 72.17
Sex (male) 439 (70%) 138
Symptomatic stenosis 139 (22%) 53
Hypertension 545 (87%) 165
Diabetes 192 (31%) 58
Cardiac disease 320 (51%) 118
Peripheral arterial disease 120 (19%) 49
Echolucent plaque 50 (8%) 4
Contralateral occlusion 52 (8%) 21
Restenosis 93 (15%) 31
NS, Not significant.early postinterventional phase, included the first 24 hoursafter leaving the operating table. Phase 5, or the late
postinterventional phase, included the interval from the
first postoperative day to 30 days.
Statistical analysis. For univariate comparisons of risk
factors and preoperative findings, statistical significance was
assessed by two-tailed 2 test with Yates corrections or the
Fisher exact test. Odds ratios and hazard ratios (HRs) with
95% confidence intervals (CIs) were calculated by standard
methods. Continuous data are expressed as mean SD. To
control for potential confounding variables regarding the
risk of stroke, multivariate analysis with conditional logistic-
regression models was used. The following variables were
included in the model: age, sex, diabetes, cardiac disease,
history of ipsilateral symptoms, contralateral occlusion,
echolucent plaque, restenosis after CEA, stent configura-
tion (open cell vs closed cell), hemodynamic instability
during CAS, and study interval (years 2001-2003 vs 2004-
2006). Significant values were considered with P  .05.
SPSS (SPSS Inc, Chicago, Ill) was used for all analyses.
Study outcomes were analyzed on an intention-to-treat
basis.
RESULTS
Characteristics of patients per study period are shown
in Table I. A total of 139 stenoses (22%) were symptomatic.
The mean age was 72.1 years (range, 49-91 years), and 438
patients (69.4%) were male.
Inability to complete CAS occurred in 32 procedures
(5.1%); 24 were converted, during the same admission (n
6) or later (n  18), to CEA. Reasons for failure included
24 inabilities to cross the stenosis and 8 inabilities to reach
the target vessel because of excessive tortuosities or calcifi-
cation in the aortic arch.
Procedures were conducted by the vascular surgeon in
charge: in detail, 76% of CAS procedures, embracing a
similar rate of neurologic complications (75%), were man-
aged by the same operator (P.C.). At 30 days, 10 major
strokes (2 of which were fatal) and 1 cardiac death oc-
curred, for an overall major stroke/death rate of 1.75%. All
strokes but one were ischemic; six were ipsilateral, three
were contralateral, and one was posterior. Four occurred in
%
2004-2006
(n  432) % P value
72.23 NS
71% 301 70% NS
27% 86 20% .05
85% 380 88% NS
30% 134 31% NS
60% 202 47% .02
25% 71 16% .01
2% 46 11% .0001
11% 31 7% NS
16% 62 14% NS3
)phase 1 and six in phase 3, whereas no major stroke oc-
er ye
8.2
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(2.9%) minor strokes were recorded.
Of 18 minor strokes, all ipsilateral, 1 occurred during
phase 1, 1 during phase 3, 11 within 24 hours (phase 4),
and 5 after 24 hours from treatment. Most TIAs (22/23),
all ipsilateral, occurred in the protected phase (phase 3).
Visible debris was collected in the CPD in 233 (37%)
CAS procedures and in 72% of those with stroke. A marked
hemodynamic response (bradycardia, hypotension, or both)
was recorded with a similar rate in CAS patients with (32%;
9/28) and without (25%; 151/599) stroke complications
(P  .4). Three myocardial infarctions occurred at 30 days
(0.5%), one of which was fatal in a patient converted to
CEA. There were no neurologic events in patients con-
verted to CEA or left on medical treatment after a failed
CAS.
Vascular-access complications occurred in 13 patients
(2.1%); 12 were due to false aneurysm formation at the
femoral puncture site. All required surgical correction. The
other was due to median nerve injury after percutaneous
left brachial access in a patient with iliac obstruction.
We specifically analyzed how the stroke rate varied over
the study period. The major and any stroke/death inci-
Fig 2. Perioperative stroke and death rate p
Table II. Results of univariate analysis on perioperative st
Risk factor
Strokes with risk
factor (n)
Age 80 y 7/90
Sex (male) 19/439
Diabetes 10/192
Cardiac disease 11/320
Symptomatic stenosis 9/139
Echolucent plaque 3/50
Contralateral occlusion 3/52
Restenosis 4/93
Open-cell stent 5/162
Hemodynamic instability 9/160
2001-2003 study period 16/195dence for each year is shown in Fig 2. Comparing the firstwith the second interval, 30-day major stroke and death
rates significantly decreased from 3.1% to 0.9% (P  .047;
odds ratio, 3.2; 95% CI, 1.1-12.1), and any stroke and
death rates decreased from 8.2% to 2.7% (P  .005; odds
ratio, 3.1; 95% CI, 1.45-6.74).
Furthermore, the timing of occurrence of major strokes
varied from the first to the last 3 years: four of the six major
strokes occurring during the first study interval (years
2001-2003) were in phase 1, whereas all four major strokes
in the years 2004 to 2006 occurred in phase 3. Results of
the univariate analysis on perioperative stroke are displayed
in Table II. According to multivariate analysis, study inter-
val (HR, 3.68; 95% CI, 1.49-9.01; P  .005), and age
(HR, 1.06; 95% CI, 1.00-1.12; P  .05) were significant
predictors of stroke.
DISCUSSION
It is evident by the recent increase in the number of
studies on CAS that CEA as the gold standard of treatment
for carotid stenosis is under challenge. Although current
evidence is generally considered to be of lower scientific
value than randomized trials, systematic reviews of obser-
vational studies are providing a source of persuasive data to
ar in 627 carotid artery stenting procedures.
Strokes without risk
factor (n) % P value
21/537 3.9 .09
9/188 4.7 .47
18/435 4.1 .34
17/307 5.5 .14
19/488 3.9 .14
25/577 4.3 .39
25/575 4.3 .41
24/534 4.5 .59
23/433 5.3 .13
19/467 4.1 .55
12/432 2.8 .003roke
%
7.7
4.4
5.2
3.4
6.4
6
5.8
4.3
3.1
5.6support CAS.5 Using the best and most recent literature,
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adverse event rate of 2.4%  0.3 in 2992 patients (3091
CAS) from 26 studies published between 2002 and 2004.
Among the different studies, the minor stroke rate was 0%
to 6%, the major stroke rate was 0% to 3%, and the death
rate was 0% to 7%. The present single-center study showed
an overall periprocedural CAS stroke/death rate of 4.6%
that decreased to 2.7% during the second study interval.
These event rates are comparable to those of current
CEA.6-11
As with any new procedure, safety is of paramount
importance, and this is especially true for CAS when com-
pared with a well-established, safe, and effective technique,
such as that used in carotid surgery. We recently analyzed
outcomes in a matched case-control study in which CAS
was compared with CEA.2 Although the difference in
major strokes was not statistically significant, the overall risk
of any periprocedural stroke was higher for CAS; stroke
incidence markedly decreased over the study period. Con-
sidering a learning-curve effect for the first 100 CAS pro-
cedures, 30-day any stroke rates decreased from 13% to
5.4%, and 30-day disabling stroke rates decreased from 4%
to 2.5%. In this study, we attempted to better define the
caseload necessary before performing safe CAS, assuming
the same 2% threshold rate for major stroke achieved for
CEA in previous studies conducted by our center.2,3 In-
deed, it was only after the first 195 CAS procedures that the
yearly major stroke risk remained stable at less than 2%.
Multivariate analysis including common stroke risk fac-
tors found that the most significant predictor of stroke was
the study interval (2001-2003 vs 2004-2006), with the first
period carrying a higher risk (HR, 3.68; 95% CI, 1.49-
9.01; P  .005). Other studies recently agreed on the
importance of a larger number of CAS interventions to
overcome the negative effects of the initial learning phase.
Ahmadi et al10 showed a significant reduction in the fre-
quency of neurologic complications (P  .03) and in the
mean duration of intervention (P  .0001) with increased
carotid experience in 320 CAS procedures performed by 1
operator at a single center.
In our study, a team consisting of one vascular surgeon
and one interventional radiologist performed every CAS
procedure. Since not everyone achieves the same level of
expertise with the same learning curve, and given that each
member of the team can learn from the experience of the
others, we found it more realistic to analyze the learning
curve of the team rather than that of the individual. We
believe, therefore, that the results are more generalized
because they are not related to the particular skills of a
single operator. Indeed, the senior operator’s results (in
76% of the CAS procedures included in this study), are
identical to those of the remaining 24%, thus proving a
similar performance among different teammembers. Other
studies have reported on a CAS learning curve with a team
approach: Lin et al,11 analyzing the effect of learning curve
on a series of 200 CAS procedures conducted by a team and
dividing the entire series into 4 groups of 50 consecutive
interventions, reached similar conclusions, with a signifi-cant reduction in the stroke/death rate from 8% to 0% (P 
.05) between the first and the last 50 procedures.
According to this experience, besides the study period,
only older age increased the stroke risk during CAS (HR,
1.06; 95% CI, 1.00-1.12; P  .05). Other risk factors
previously identified as significant predictors of periproce-
dural stroke, such as symptomatic lesions and plaque mor-
phology, did not seem to influence the outcome.12-14
Regarding plaque analysis, we did not consider the gray-
scale median classification14 because this methodology is
still debated and because its reproducibility is not fully
accepted.
The low incidence of cerebral hemorrhage and cardiac
complications compares favorably with other results of CAS
in the literature.15-17 The careful pressure monitoring dur-
ing and shortly after the procedure may explain these
findings.
In-depth analysis of the timing of complications
showed that phase 1 (catheterization or diagnostic phase)
and phase 3 (stent-ballooning phase) seemed to be the
most hazardous steps for CAS; all major strokes occurred
during these two phases. However, the 4 major strokes
occurring before CPD placement (phase 1) were recorded
during the first 195 procedures, whereas no major event
occurred during phase 1 in the last study interval.
Hammer et al12 specifically analyzed the embolism risk
in 53 CAS patients by systematic application of cerebral
diffusion-weighted magnetic resonance imaging 24 hours
before and 5 to 30 hours after the procedure. The authors
found new ischemic lesions in approximately 40% (n 21)
of the patients, although these were symptomatic only in
4% (n 2). It is interesting to note that in 62% (13/21) of
the positive diffusion-weighted magnetic resonance imag-
ing cases, embolic lesions were found outside the vascular
territory of the treated internal carotid artery, thus suggest-
ing embolization from the aortic arch. These findings
showed that embolization originating from sources proxi-
mal to the treated lesion is a relatively frequent and not
completely avoidable event, but the significance of such
clinically silent embolization should be of concern, espe-
cially in an elderly population and in patients with impaired
brain function or previous cerebral infarction. Conversely,
embolic events originating from the catheter, wire, or
sheath manipulation in the aortic arch and the common
carotid artery cannot be excluded.
In our study, six major strokes occurred during the
ballooning/stent phase. Visible debris was recovered in
the CPD in 72% of patients with major strokes vs 37% of
the overall study group. The presence of CPD could not
prevent all the embolic risks of CAS, and it is obvious that
placement of CPD may add complexity and additional
instrumentation to the angioplasty and stent-placement
procedure. Crossing a high-grade stenosis may be very
challenging and may increase the risk of dissection or other
damage to the vessel wall. However, CPDs have been
largely recommended for CAS because their benefits could
greatly outweigh the risks inherent to the use.12 Techno-
logical improvement, including filters with a better crossing
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ate, may increase the appropriateness of these devices in
preventing intraprocedural embolization. In this study, in
all but seven procedures, distal filters were used as CPDs,
and in most cases (82% in the first period and 72% in the
second) a single brand was used (FilterWire EZ). This
technical approach did not allow us to make any meaning-
ful comparison between different types of filters.
The sharp decline of all neurologic complications dur-
ing the study period and its different occurrence according
to the different phases of the procedure may be due to
multiple factors, but certainly a learning-curve effect cannot
be ignored, both in terms of better selection of the patients
(eg, avoiding severely diseased aortic arches) and of a more
careful manipulation of wires and catheters in approaching
the target lesion. According to the steady decline of major
neurologic complications, we extended indications for CAS
to low-risk patients with carotid stenosis, as can be deduced
from the relative reduction of symptomatic and noncoro-
nary patients treated. Similarly, the higher incidence of
patients with echolucent plaque shows an attitude toward
generalizing the indications (Table I).
Finally, most of the 18 minor strokes recorded oc-
curred in the last phases: 16 occurred after the end of the
procedure, and 5 occurred after 24 hours. The frequent late
occurrence of these minor events is difficult to explain:
probably selection of stent material and design and appro-
priate antiaggregation may play a role.18-20 Although we
cannot completely exclude that in few cases subtle symp-
toms indicating mild neurologic events may be overlooked
during the procedure and recognized later, further studies
assessing the specific role of technology improvements,
stent adaptability (stiffness vs flexible material), or plaque
scaffolding (open-cell vs close-cell design) and coverage
will be most helpful. Furthermore, the adjunctive benefit of
medical therapy is far from being clarified.
Our study presents some limitations: it was a nonran-
domized study, and the progressive extension of the
indications due to the declining complication rate may
have produced selection biases between the populations of
the two periods. The role of chance may have affected the
yearly occurrence of complications. This study was a single-
center experience, and we should be cautious in extending
these results to other centers.
CONCLUSIONS
The effect of the learning curve related to technical
expertise and patient selection may influence the results of
CAS. Our data show that the CAS caseload should be large
enough to ensure a major complication rate of less than 2%.
This experience attempts to reduce strokes that may occur
during the unprotected phase of catheterization and the
approach to the target vessel. Moreover, expertise in select-
ing the material and design of the stent according to
different vessel morphology, in association with correct
medical treatment, may be useful in reducing the number
of minor strokes that occur in the later postinterventionalphases of CAS. Team experience, knowledge of endovas-
cular materials and medications, and the ability to navigate
through a difficult aortic arch and to cross and treat chal-
lenging lesions can ensure CAS safety. Until results of
randomized trials are available, CAS may be considered an
alternative treatment option for carotid revascularization in
experienced centers.
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Dr Richard Powell (Lebanon, NH). The Guidant 2500 data
were recently presented, and one of the conclusions of that study
was that the low-volume operators had equivalent results with the
high-volume operators following their prescribed training course.
I was just wondering if you would comment on that, especially in
light of your study, which shows that, if anything, more cases may
be required.
Dr Cao. I have no real comment on that. This is a single-
center with independent results. It’s striking to see how the first
interval carries a higher risk with a protective device. In our
experience, the learning curve was still a crucial aspect of our
results.
Dr Marc Bosiers (Dendermonde, Belgium). All 18 observed
minor strokes occurred in the postprocedural phase. Was any
correlation observed between the selected stent types and the
number of observed events? What could be the reasoning?
In the EVA-3S study, the controlled randomized trial com-
paring CAS vs CEA in France, which is going to be published, CEA
turns out to be superior over CAS. Taking into account this
publication, I would like to hear your comment on the required
study credentials: an experience of minimally 50 to 100 CEA
procedures is required, while participating centers only need 10 to
15 documented CAS cases.
Dr Cao. Regarding the stent configuration, we have not
enough numbers to evaluate the difference; also, many events
occurred during the unprotected phase. Consequently, we would
need a very large sample size.
As to the learning curve, I completely agree with you. The
main problem of all randomized trials, including the technical
aspect, is that centers with an incomplete learning curve can be
recruited. So, probably, to fully evaluate the results of different
techniques in randomized trials, we should be careful to select
centers with adequate track records.
Dr Munier Nazzal (Toledo, Ohio). I have one question re-
garding the catheter experience. Did you look at catheter experi-
ence in other vessels? Because the operators might be new in the
carotid, but they do other procedures, like renal, which might be
more difficult even sometimes than carotid.
Dr Cao. Let me first specify that our cases were done in the
operating room with a fixed imaging system during the last 6
months. Previously a digitalized mobile system was used, with a
team made of a radiologist with a large experience of catheteriza-
tion and a vascular surgeon. I think that the background of the
team was adequate.
Dr Robert Hobson (Newark, NJ). Dr Cao, I appreciated
your presentation. It’s what we have come to expect from the
University of Perugia.
My question has to do with your calculation of a learning
curve. The CREST investigators here in North America and our
biostatistical associates have been working on a similar project. It’s
particularly difficult to perform these analyses when you have a low
number of end points, as you do, and the excellence of your workHowever, I noticed that you did not recommend a number of
cases that you think is appropriate for a vascular surgeon to then
proceed independently with carotid artery stenting. The Interven-
tional Management Committee of CREST has put this figure at
about 30 cases. But if you look at the biostatistics of this question,
it may be as low as 15 cases, which reinforces Dr Powell’s com-
ments about Guidant’s ARCHeR data in that “experienced” inter-
ventionalists did as well as more experienced clinicians. If you
could please review your method of analysis on the learning curve,
perhaps you can then recommend an appropriate number of cases.
Finally, like Dr Bosiers, do you have any insight on the results
of the EVA-3S trial, which apparently demonstrated a benefit for
endarterectomy over stenting.
Dr Cao. In our study we included all the cases of carotid
stenting, trying to localize the time of occurrence of the compli-
cation. I think this is quite crucial, because many other reports, in
my opinion, didn’t focus on this topic.
With regard to the caseload, I think we cannot generalize our
results. A person can be trained in different ways, with a proctor,
going to other centers, and so on. For sure, according to our
experience, the previously suggested number seems quite low to
assure safety of carotid stenting.
Dr John Ricotta (Stony Brook, NY). Dr Cao, excellent pre-
sentation, and I want to thank you for starting me on my learning
curve several months ago. I have two questions for you.
It seemed tome that in the second period, you liberalized your
indications for stenting. You were stenting people with less periph-
eral vascular disease and less coronary disease. I wonder if you
would comment on whether you think that influenced the out-
come of your patients. Do you think that the patient groups were
similar, or do you think that as you liberalized your indication for
stenting, you were actually doing stenting on a safer group of
patients?
I also have a comment, similar to what other people have said:
if we’re going to start on a learning curve, somehow you have to
get to 200 cases. What suggestions do you have for us to select
patients between number 10 and number 200?
Dr Cao. I was aware that by presenting 200 cases as a learning
curve, most of the vascular surgeons would shoot me, because it
makes the starting experience very difficult. I would say, again, that
these results are not intended to be guidelines. I would suggest to
start with patients with easy-access vessels, low-risk patients, pos-
sibly with a team approach including different specialties.
Regarding the possible selection bias of the results, we have
pointed out that this is not a randomized study. With multivariable
analysis, we showed that patient characteristics were not predictors
of complications.
Dr Marc Schermerhorn (Boston, Mass). In your analysis, age
was a weak predictor of outcome, but it looked like you were
analyzing it as a continuous variable. Did you look at it as a dichoto-
mous variable? What were the stroke rates above and below 80?
